


Pathway for treatment of Psoriatic Arthritis in adults.

Key to terms:
DMARD: disease-modifying anti-rheumatic drug
ILi: interleukin inhibitors that target type 17,12 or 12/23 interleukins
JAKi: Janus kinase inhibitor
MTX: methotrexate
PASI 75 response: reduction in psoriasis area severity index (PASI) score of at least 75% from baseline
PsARC: psoriatic arthritis response criteria
TA: NICE technology appraisal
TNFi: tumour necrosis factor inhibitor



BOX 1. First line biologic treatment options

Usually start treatment with least expensive appropriate treatment
 Options listed by mechanism of action and overall cost from left to right

TNFi: **Adalimumab biosimilar TA199 – usual first line choice.**
 Etanercept biosimilar TA199, Infliximab biosimilar TA199, Certolizumab TA445, Golimumab TA220

JAKi: Upadacitinib TA768, Tofacitinib (with MTX) TA543

IL-17i: Secukinumab 150mg TA445, Bimekizumab TA916, Ixekizumab TA537, Secukinumab 300mg TA445 **see Note 1**

IL-23i: Guselkumab NICE TA 815 **see Note 2**

IL-12 /IL-23i: Ustekinumab TA340 **see Note 3**

Box1.a First line apremilast

Apremilast (TA 433) oral tablet

Apremilast is a clinically effective treatment compared with placebo but not as clinically effective as TNFis.

For use in patients who are needle phobic for whom JAKi (oral tablets) are not appropriate or are contraindicated.

In line with TA433 apremilast is NOT commissioned for use after TNFi.

Assess Response. Relevant NICE TAs state that the first response should be measured at 12 weeks - 24 weeks depending on treatment modality.

Adequate response to treatment is defined as:

- improvement in at least 2 of the 4 PsARC Criteria (**see Note 4**), 1 of which must be the joint tenderness or swelling score

AND

- no worsening in any of the 4 criteria

For patients whose PsARC response does not justify continuation of treatment but who have psoriasis and a PASI 75 response, treatment should be assessed by a dermatologist to determine whether continuing is appropriate on the basis of skin response. (**See Note 5**)

BOX 2. Second line treatment options

Consider alternative treatment from a different class. The least expensive appropriate treatment should be chosen.

TNFi listed in BOX 1 may be used second line (local agreement) also **see Note 6**

JAKi: Upadacitinib TA768, Tofacitinib (with MTX) TA543

IL-17i: Secukinumab 150mg TA445, Bimekizumab TA916, Ixekizumab TA537, Secukinumab 300mg TA445 **see Note 1**

IL-23i: Guselkumab TA815 **see Note 7**, Risankizumab TA803 **see Note 8**

IL-12 /IL-23i: Ustekinumab TA340

Assess response as for first line. Stop treatment if adequate response not maintained / intolerance and consider next pathway step

BOX 3. Third, fourth- and fifth-line treatment options (TAs and local agreement)

Consider alternative treatment from a different class. The least expensive appropriate treatment should be chosen

JAKi: Upadacitinib TA768, Tofacitinib (with MTX) TA543

IL-17i: Secukinumab 150mg TA445, Bimekizumab TA916, Ixekizumab TA537, Secukinumab 300mg TA445 **see Note 1**

IL-23i: Guselkumab TA815 **see Note 7**, Risankizumab TA803 **see Note 8**

IL-12 /IL-23i: Ustekinumab TA340

Assess response as for first line. Stop treatment if adequate response not maintained / intolerance and consider next pathway step.

If treatment not tolerated, or no response or inadequate response, or loss of response move to next line in pathway

If treatment is tolerated and there is adequate response
 Maintain same treatment and monitor patient and PsARC. Clinical review to be carried out at 6-12 monthly intervals.
 Stop treatment if adequate response not maintained / intolerance and consider next pathway step

NOTE 1: Cost order is dependent on dose :secukinumab 150mg maintenance dose is less expensive than bimekizumab and ixekizumab, secukinumab 300mg maintenance dose is more expensive than bimekizumab and ixekizumab.

NOTE 2: Guselkumab is only commissioned first line if TNFi are contra-indicated.

NOTE 3: Ustekinumab is only commissioned first line if TNFi are contra-indicated.

NOTE 4: The PsARC comprises:

- A patient global self-assessment (on a 0–5 Likert scale); a physician global assessment (on a 0–5 Likert scale) with improvement defined as a decrease by at least 1 unit, and worsening defined as an increase by at least 1 unit)
- A tender joint score: a swollen joint score (with improvement defined as a decrease of at least 30%, and worsening defined as an increase of at least 30% from baseline).

NOTE 5: see local pathway and TAs103,134,146,180,350, 419,442,574,521 and 596 for guidance on the use of biologic drugs for the treatment of Psoriasis

NOTE 6: certolizumab is only commissioned second line if disease has stopped responding **after** the first 12 weeks of 1st line TNFi

NOTE 7: A reduced dose interval of 4 weekly is not routinely commissioned for guselkumab

NOTE 8: Risankizumab is only commissioned for patients who have had at least one biologic treatment and also have moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10. If both guselkumab and risankizumab are suitable the least costly treatment should be chosen.

Maximum of five sequential treatments per patient are routinely commissioned.

Version	3.0
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	November 2023
Developed by	Pharmacy and Medicines Optimisation Team Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
Review Date	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available
Superseded version	V1.0 Risankizumab added up to 5 th line and guselkumab criteria amended, in line with NICE TA 803 and 815 and existing pathway principles. V2.0 Bimekizumab added up to 5 th line, in line with NICE TA 916 and existing pathway principles.